AI Article Synopsis
- A fluorinated phthalocyanine was compared to its non-fluorinated version to assess how fluorination affects their photophysical, photochemical, and redox properties, as well as their biological activity.
- The study explored the drugs' abilities to interact with biological membranes and proteins, while developing a water-dispersible formulation using Pluronic triblock copolymer micelles to enhance delivery and reduce self-aggregation.
- The results indicated that the incorporation of phthalocyanines into micelles improved cellular uptake and photocytotoxicity, with the fluorinated variant showing the best efficacy in tumor growth inhibition, leading to complete regression in some mice.
Article Abstract
A fluorinated phthalocyanine and its non-fluorinated analogue were selected to evaluate the potential enhancement of fluorination on photophysical, photochemical and redox properties as well as on biological activity in cellular and animal models. Due to the pharmacological relevance, the affinity of these phthalocyanines towards biological membranes (logP) as well as their primary interaction with human serum albumin (HSA) or low-density lipoprotein (LDL) were determined. Water-dispersible drug formulation of phthalocyanines via Pluronic-based triblock copolymer micelles was prepared to avoid self-aggregation effects and to improve their delivery. The obtained results demonstrate that phthalocyanines incorporation into tunable-polymeric micelles significantly enhanced their cellular uptake and their photocytotoxicity. The improved biodistribution and photodynamic efficacy of the phthalocyanines-triblock copolymer conjugates was also confirmed in vivo in CT26 bearing BALB/c mice. PDT with both compounds led to tumor growth inhibition in all treated animals. Fluorinated phthalocyanine 2 turned out to be the most effective anticancer agent as the tumors of 20% of mice treated regressed completely and did not appear for over one year after treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2016.08.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fullerene (C & C)-Meso-Tris-4-Carboxyphenyl Porphyrin Dyads Inhibit Entry of Wild-Type and Drug-Resistant HIV-1 Clades B and C.
J Med Virol
February 2025
Department of Chemistry, Assam University, Silchar, India.
The biological applications of noncationic porphyrin-fullerene (P-F) dyads as anti-HIV agents have been limited despite the established use of several cationic P-F dyads as anti-cancer photodynamic therapy (PDT) agents. This article explores the potential of amphiphilic non-cationic porphyrin-fullerene dyads as HIV-1 inhibitors under both PDT (light-treated) and non-PDT (dark) conditions. The amphiphilic P-F dyads, PBC and PBC, demonstrated enhanced efficacy in inhibiting the entry and production of HIV-1 (subtypes B and C).
View Article and Find Full Text PDFRecent advances in near-infrared organic photosensitizers for photodynamic cancer therapy.
Biomater Sci
January 2025
School of Chemistry and Life Sciences, Hanoi University of Science and Technology, 1 Dai Co Viet Road, Ha Noi, Vietnam.
With the advancement of photodynamic therapy, various photosensitizers have been developed to enhance the efficacy of cancer treatment while minimizing side effects. Recently, near-infrared organic fluorophores have gained significant attention as promising photodynamic agents for cancer therapy due to their tunable photophysical properties, structural versatility, good biocompatibility, high biosafety, and synthetic flexibility. In particular, near-infrared organic photosensitizers offer several notable advantages, including deep tissue penetration, a low fluorescence background for bioimaging, and reduced damage to biological tissues compared to traditional visible-spectrum photosensitizers.
View Article and Find Full Text PDFA Multifunctional MIL-101-NH(Fe) Nanoplatform for Synergistic Melanoma Therapy.
Int J Nanomedicine
January 2025
Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Background: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.
Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG).
Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma.
Mater Today Bio
February 2025
Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Hepatocellular carcinoma (HCC) is typically diagnosed at intermediate to advanced stage, making surgical treatment unfeasible. Conversion therapy aims to reduce tumor stage, improve hepatic resection feasibility, and lower recurrence rates. Since traditional therapies are often accompanied by uncertainty of efficacy, there is an urgent need to explore new treatment strategies.
View Article and Find Full Text PDFNevoid basal cell carcinoma syndrome (Gorlin syndrome): a case report.
J Med Case Rep
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Background: Basal cell nevus syndrome, also known as Gorlin or Gorlin-Goltz syndrome, is a hereditary condition caused by mutation in the PATCHED gene. The syndrome presents with a wide range of clinical manifestations, including basal cell carcinomas, jaw cysts, and skeletal anomalies. Diagnosis is based on specific criteria, and treatment typically includes surgical removal of basal cell carcinomas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!